منابع مشابه
Prognostic markers for urologic cancers.
© The Canadian Journal of UrologyTM; 23(1); February 2016 Address correspondence to Dr. Jay D. Raman, Department of Urology, Penn State Milton S. Hershey Medical Center, 500 University Drive, BMR c4830F, Hershey, PA 17033 USA Prognostic markers for urologic cancers Jay D. Raman, MD Department of Urology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA Referring to the ar...
متن کاملEpigenetic therapy in urologic cancers: an update on clinical trials
Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA expression. Since these changes are reversible, efforts are being made to develop epigenetic drugs that restore the normal epigenetic patterns of cell...
متن کاملDiagnostic Value of MicroRNAs for Urologic Cancers
MicroRNAs (miRNAs), particularly those extracted from the blood or tissues, have become the focus of urologic cancers research. However, the literature reviews on the accuracy of miRNA detection in urologic cancers have been inconsistent, leading us to perform this meta-analysis. Eligible studies were searched in PubMed and other databases. To calculate the pooled detection accuracy estimates, ...
متن کاملAssociation between colorectal cancer and urologic cancers.
BACKGROUND Different types of urologic cancers have been associated with colorectal cancer (CRC) in hereditary nonpolyposis CRC, but it is still unknown whether there is an association between urologic cancer and CRC in the general population. We sought to quantify the risk for CRC after urologic cancer and the risk for urologic cancer after CRC in patients without known genetic syndromes. ME...
متن کاملMolecular therapy in urologic oncology.
During recent years, significant advances have been made in the field of molecular therapy in urologic oncology, mainly for advanced renal cell carcinoma. In this hitherto largely treatment-refractory disease, several agents have been developed targeting the von Hippel-Lindau metabolic pathway which is involved in carcinogenesis and progression of the majority of renal cell carcinomas. Although...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Clinical Practice Urology
سال: 2006
ISSN: 1743-4270,1743-4289
DOI: 10.1038/ncpuro0583